v3.26.1
Segment reporting (Details)
₨ in Millions, $ in Millions
 12 Months Ended
Mar. 31, 2026
INR (₨)
Mar. 31, 2026
USD ($)
Mar. 31, 2025
INR (₨)
Mar. 31, 2024
INR (₨)
Disclosure of operating segments [line items]        
Revenues ₨ 335,933 [1] $ 3,580 ₨ 325,535 [1] ₨ 279,164 [1]
Gross Profit 177,264 1,889 190,428 163,607
Selling, general and administrative expenses 106,763 1,137 93,870 77,201
Research and development expenses 24,058 256 27,380 22,873
Impairment of non-current assets, net 3,519 38 1,693 3
Other income, net (7,627) (81) (4,358) (4,199)
Results from operating activities 50,551 539 71,843 67,729
Finance income, net 4,132 44 4,724 3,994
Share of profit of equity accounted investees, net of tax 134 1 217 147
Profit before tax 54,817 584 76,784 71,870
Tax expense, net 12,351 132 19,539 16,186
Profit for the year 42,466 $ 452 57,245 55,684
Global Generics [Member]        
Disclosure of operating segments [line items]        
Revenues [1] 299,033   289,552 245,453
Gross Profit 169,698   179,606 154,268
Pharmaceutical Services and Active Ingredients [Member]        
Disclosure of operating segments [line items]        
Revenues [1] 34,773   33,846 29,801
Gross Profit 5,984   9,157 6,919
Other segment [Member]        
Disclosure of operating segments [line items]        
Revenues [1] 2,127   2,137 3,910
Gross Profit ₨ 1,582   ₨ 1,665 ₨ 2,420
[1] Revenues for the year ended March 31, 2026 do not include inter-segment revenues from the PSAI segment to the Global Generics segment, of Rs.7,270 (as compared to Rs.9,389 and Rs.10,707 for the years ended March 31, 2025 and 2024, respectively) and from the PSAI segment to the Others segment of Rs.0 (as compared to Rs.0 and Rs.72 for the years ended March 31, 2025 and 2024, respectively)